Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Experimental Medicine (JEM)Microbiome Influencers of Checkpoint Blockade–associated Toxicity

Although immune therapies, such as immune checkpoint inhibitors (ICIs), have significantly improved cancer outcomes, these therapies can also cause off-target tissue damage and response variability. The host microbiome affects ICI responsiveness and risk of immune-related adverse effects (irAEs), according to numerous lines of evidence. These developments show the possibility to control microbiome elements to improve the success of ICI because the microbiome is manipulable.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form